ATXN2 and spinocerebellar ataxia type 2: Similarly, ICV administration of non-allele specific ASO targeting ATXN2 significantly reduced the expression of ATXN2 and ameliorated the motor deficit in two different mice models of SCA2 (Scoles et al., 2017).